Fernandez Hazim Carol, Duarte Gustavo, Urena Ana P, Jain Swati, Mishra Rishabh, Vittorio Timothy J, Rodriguez-Guerra Miguel
Department of Medicine, Montefiore Medical Center, Wakefield Campus, Bronx, NY, USA.
Cleveland Clinic, Weston, FL, USA.
Drugs Context. 2023 Dec 29;12. doi: 10.7573/dic.2023-6-5. eCollection 2023.
Diuresis with loop diuretics is the mainstay treatment for volume optimization in patients with congestive heart failure, in which perfusion and volume expansion play a crucial role. There are robust guidelines with extensive evidence for the management of heart failure; however, clear guidance is needed for patients who do not respond to standard diuretic treatment. Diuretic resistance (DR) can be defined as an insufficient quantity of natriuresis with proper diuretic therapy. A combination of diuretic regimens is used to overcome DR and, more recently, SGLT2 inhibitors have been shown to improve diuresis. Despite DR being relatively common, it is challenging to treat and there remains a notable lack of substantial data guiding its management. Moreover, DR has been linked with poor prognosis. This review aims to expose the multiple approaches for treatment of patients with DR and the importance of intravascular volume expansion in the response to therapy.
使用袢利尿剂进行利尿是充血性心力衰竭患者进行容量优化的主要治疗方法,其中灌注和容量扩张起着关键作用。对于心力衰竭的管理,有强有力的指南且有大量证据;然而,对于对标准利尿剂治疗无反应的患者,需要明确的指导。利尿剂抵抗(DR)可定义为在适当的利尿剂治疗下,钠利尿量不足。联合使用利尿剂方案以克服DR,最近,已证明钠-葡萄糖协同转运蛋白2(SGLT2)抑制剂可改善利尿。尽管DR相对常见,但治疗具有挑战性,并且仍然明显缺乏指导其管理的实质性数据。此外,DR与不良预后相关。本综述旨在揭示治疗DR患者的多种方法以及血管内容量扩张在治疗反应中的重要性。